Celldex Therapeutics, Inc. Sure Loves Mondays

By Brian OrelliFool.com

What: Celldex Therapeutics ended the day up more than 10% on no news.

Continue Reading Below

So what: Celldex's investors certainly like Mondays. Two weeks ago the stock started the week with a double-digit move higher -- also on no news. Shares in the biotech are now about 50% higher than their 52-week low.

Unfortunately, after the biotech's brain cancer vaccine Rintegafaileda clinical trial last month,Celldex is still nowhere near its 52-week high, either.

CLDXdata byYCharts.

Now what: Celldex has other drugs in its pipeline besides Rintega. Glembatumumab vedotin provides most of the current valuation since the drug is already in a registration trial, testing the activity in a subset of breast cancer patients.

Unfortunately the METRIC trial in breast cancer isn't scheduled to read out until 2017. The drug is also being tested in a few other phase 2 trials in other cancers that could report data sooner and might increase the valuation some more.

But Celldex has a ways to go before it'll have a drug on the market, and given the waiting game, the biotech is likely to trade up and down on the whim of traders rather than the sentiment of long-term investors.

The article Celldex Therapeutics, Inc. Sure Loves Mondays originally appeared on Fool.com.

Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Celldex Therapeutics. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright 1995 - 2016 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.